On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial conducted in more than 15,000 adults in the United Kingdom had been published in a manuscript posted to the preprint server medRxiv.

Conclusions stated that a two-dose regimen of Novavaxﾒ COVID-19 vaccine candidate, NVX-CoV2373, conferred nearly 90% protection against a blend of prototype and variant COVID-19, demonstrated high efficacy against the B.1.1.7 variant, and demonstrated a reassuring safety profile.